Medtronic has received both U.S. Food and Drug Administration as well as CE Mark approval for our newest device safeguard, the Lead Integrity Alert™ (LIA) software – an important milestone in company’s broader innovation strategy, and one which demonstrates continued commitment to patients. LIA was designed to provide patients with certain Medtronic defibrillators and defibrillator leads with more advance notice – via an audible sound – of a potential lead fracture that could result in an unnecessary shock.
Medtronic commitment to improving the lives of patients with heart disease led to the development of LIA, which offers additional protection for defibrillator patients and a new level of technology for clinicians.
Kenneth A. Ellenbogen, M.D., Kontos Professor of Cardiology at the Medical College of Virginia, who worked with Medtronic on LIA, recently stated his views on the product said, I was involved in early discussions of this product, and have studied its clinical impact throughout its development. I think LIA is an example of innovation that advances medical care. I will use LIA to protect my ICD patients against unnecessary shocks that can result from lead fractures.
